Cellulose Derivatives Patents (Class 424/494)
  • Patent number: 10443022
    Abstract: The present invention is a solid fabric care composition comprising a water-soluble carrier, a water-soluble polymer, a fabric care compound, a polysaccharide and a fragrance, wherein the water-soluble carrier is in particle form, having a coating comprising the water-soluble polymer and the fragrance, and a mixture of the fabric care compound and the polysaccharide being incorporated at least partly into the coating, or the coating of the water-soluble carrier being coated at least partly with a mixture of the fabric care compound and the polysaccharide. Also described herein are fabric care washing or cleaning products comprising the fabric care compositions.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 15, 2019
    Assignee: Henkel AG & Co. KGaA
    Inventors: Noelle Wrubbel, Karl-Heinz Scheffler, Daniel Tigges, Rene-Andres Artiga Gonzalez, Matthias Sunder, Mario Sturm, Tobias Segler, Konstanze Mayer
  • Patent number: 10179110
    Abstract: An aqueous composition comprising at least 10 weight percent of a dispersed esterified cellulose ether, based on the total weight of the aqueous composition, wherein the esterified cellulose ether comprises (i) groups of the formula —C(O)—R—COOH or (ii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOH, R being a divalent aliphatic or aromatic hydrocarbon group, and at least a part of the groups —C(O)—R—COOH are neutralized with an ammonium salt of carbonic acid, formic acid or acetic acid, and wherein d90 of the dispersed esterified cellulose ether particles is up to 10 micrometers, d90 being the diameter where 90 mass percent of the particles have a smaller equivalent diameter and the other 10 mass percent have a larger equivalent diameter, is useful for preparing coating dosage forms including tablets, capsules and others, or for the formation of capsules shells.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: January 15, 2019
    Assignee: Dow Global Technologies LLC
    Inventors: Jin Zhao, Roland Adden, Neal J. Fetner, David L. Malotky
  • Patent number: 10137091
    Abstract: In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released immediately following administration and again at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released before sleep and while a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for an immediate, followed by a delayed release of drug.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: November 27, 2018
    Assignee: UNIVERSITY OF STRATHCLYDE
    Inventors: Alexander Mullen, Howard Stevens, Sarah Eccleston
  • Patent number: 10071088
    Abstract: Methods and compositions are disclosed for reducing Post Operative Nausea and/or Vomiting (PONV) in a human patient in need of general anesthesia. Such methods may include scheduling surgery for the human patient and administering to the patient one or more series of prescribed medicines days during a regimen preceding general anesthesia to condition receptors involved in the nausea and/or vomiting reflex.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: September 11, 2018
    Inventor: C. Andrew Fleming
  • Patent number: 9943488
    Abstract: A granule including a solid core on which is supported an active ingredient, said active ingredient being selected from gamma-hydroxybutric acid or one of its pharmaceutically acceptable salts, said granule further including, supported on said solid core, one or more compounds which may generate gas evolvement, one or more diluents, said granule being in that it is coated with a membrane, and in that the solid core represents from 15% to 50% by weight based on the total weight of the granule.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: April 17, 2018
    Assignee: DEBREGEAS ET ASSOCIES PHARMA
    Inventors: Pascal Suplie, Sylvie Lecoustey
  • Patent number: 9925174
    Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Ulrich Brauns
  • Patent number: 9642803
    Abstract: Nano-sized particles are provided comprising at least one multi-headed amphiphilic compound, in which at least one headgroup of said multi-headed amphiphilic compound is selectively cleavable or contains a selectively cleavable group, and at least one biologically active agent, which is both encapsulated within the nano-particle and non-covalently associated thereto.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: May 9, 2017
    Assignee: Ben-Gurion University Of The Negev Research And Development Authority
    Inventors: Charles Linder, Sarina Grinberg, Eliahu Heldman
  • Patent number: 9486446
    Abstract: The present invention provides an orally-disintegrating solid preparation comprising fine granules showing controlled release of a pharmaceutically active ingredient, wherein the outermost layer of the fine granules is coated with a coating layer comprising hydroxypropylmethylcellulose and low-substituted hydroxypropylcellulose and breakage of the fine granules during tableting is suppressed.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: November 8, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takashi Kurasawa, Yasuko Watanabe, Yohko Akiyama
  • Patent number: 9474719
    Abstract: In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a pulse at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released while a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a pulsed release of drug.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: October 25, 2016
    Assignee: UNIVERSITY OF STRATHCLYDE
    Inventors: Alexander Mullen, Howard Stevens, Sarah Eccleston
  • Patent number: 9415013
    Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: August 16, 2016
    Assignee: TheraVida, Inc.
    Inventors: Mehdi Paborji, Robert V. Tuohy, III, Peter R. P. Freed, Roger S. Flugel
  • Patent number: 9416097
    Abstract: The invention provides crystalline minocycline base. In particular, three crystalline polymorphic forms, designated Form I, Form II and Form III, of minocycline base are provided. These are characterized by XRD and IR data. Processes for preparing the new polymorphic forms are also provided. For example, Form I is prepared by dissolving and/or suspending amorphous minocycline base in an organic solvent chosen from ethers followed by crystallization from the mixture.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: August 16, 2016
    Assignee: Hovione Scientia Limited
    Inventors: Zita Mendes, Jose Rafael Antunes, Susana Marto, William Heggie
  • Patent number: 9301957
    Abstract: A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: April 5, 2016
    Assignee: Novartis AG
    Inventors: Upkar Bhardwaj, Ann Reese Comfort, Ping Li, Shoufeng Li, Alexey Makarov, Mangesh Sadashiv Bordawekar
  • Patent number: 9241956
    Abstract: A pharmaceutical composition for use in oral medication for the treatment of diabetes mellitus can include an antacid agent with an enteric coating, which permits the antacid agent to be delivered in the small intestine where it reduces acidity thereby causing a lowering of blood sugar levels. The pharmaceutical composition can be packaged in various tablet forms, including standard tablets and multiple pellet tablets. The pharmaceutical composition can further include a composition for treatment of diabetes, such as metformin, in enteric or non-enteric formulations. The pharmaceutical composition can further include an enteric-coated gastric acid secretion inhibitor. Also disclosed are methods for the treatment of diabetes mellitus, using the pharmaceutical composition and its variants.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: January 26, 2016
    Inventors: Kenneth John Tibbs, Dawn Ann Tibbs
  • Patent number: 9120031
    Abstract: Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. The relative additive concentration may have a continuous rate of change across the finite gradient. In some examples, an active substance: additive ratio of the particle surface is sufficiently low to form a protective surface layer around the active substance. Generally, the particle surface is free of the active substance.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: September 1, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Mazen H. Hanna, Peter York
  • Patent number: 9078811
    Abstract: Methods for increasing the oral bioavailability of tetracycline compounds are described.
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: July 14, 2015
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Michael N. Alekshun, Adel Bakhtyari, Sean Johnston, Masha Pukshansky
  • Publication number: 20150140092
    Abstract: The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.
    Type: Application
    Filed: November 17, 2014
    Publication date: May 21, 2015
    Inventor: Guru V. BETAGERI
  • Publication number: 20150140091
    Abstract: A solid dispersion comprising at least one active ingredient in at least one hydroxyalkyl methylcellulose having a DS of from 1.0 to 2.7 and an MS of from 0.40 to 1.30, wherein DS is the degree of substitution of methoxyl groups and MS is the molar substitution of hydroxyalkoxyl groups, can be produced by extrusion or spray-drying.
    Type: Application
    Filed: July 12, 2013
    Publication date: May 21, 2015
    Applicant: Dow Global Technologies LLC
    Inventors: Nicholas S. Grasman, Steven J. Guillaudeu, Mark J. Hall, Uma Shrestha, Maureen L. Rose, William W. Porter, III, Wesley J. Spaulding, Kevin P. O'donnell, True L. Rogers
  • Patent number: 9034902
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 19, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 9034395
    Abstract: Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: May 19, 2015
    Assignee: GW Pharma Limited
    Inventors: Brian Whittle, Geoffrey Guy, David Downs, David W. Pate
  • Publication number: 20150132396
    Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Applicant: SIGMOID PHARMA LIMITED
    Inventors: Ivan Coulter, Vincenzo Aversa, Mónica Rosa, Bernard Francis McDonald
  • Publication number: 20150125521
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Application
    Filed: January 5, 2015
    Publication date: May 7, 2015
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 9023400
    Abstract: Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: May 5, 2015
    Assignee: Flamel Technologies
    Inventors: Florence Guimberteau, Frederic Dargelas
  • Patent number: 9023389
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: May 5, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Publication number: 20150118317
    Abstract: Various fenofibrate dosage forms contain a plurality of beads or particles, where the beads or particles include a pharmaceutical composition comprising fenofibrate; from 0.3% to 10% by weight of the beads or particles of a surfactant; and from about 5% to about 15% by weight of the beads or particles of a water soluble or water dispersible cellulosic binder. The mass ratio of the drug to the binder in the dosage form is between about 3.5:1 and 4.5:1; and the dosage form produces a first Cmax in vivo that is between about 10% and about 50% higher than a comparative Cmax produced by a comparative dosage form. The comparative dosage form comprises the drug and the binder in a ratio of between about 5:1 and 15:1.
    Type: Application
    Filed: October 23, 2012
    Publication date: April 30, 2015
    Applicant: MYLAN, INC.
    Inventors: Sarat C. Chattaraj, Glenn Allen Redelman, Andrew Alan Shaw
  • Patent number: 9017731
    Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. In a particular embodiment, the drug dosage form comprises a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 28, 2015
    Assignee: Neos Therapeutics, LP
    Inventors: Mark Tengler, Russell McMahen
  • Patent number: 9011926
    Abstract: In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: April 21, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Naoki Nagahara, Naoki Asakawa, Muneo Nonomura
  • Patent number: 9005658
    Abstract: A pharmaceutical pellet is provided, comprising a spherical core containing the active substance with a smooth surface and a coating on the core, which controls pH-independent release of the active substance. With a pellet of this kind, the release of the active substance may follow a profile with a lag-phase from 60 minutes to 840 minutes, where during the lag-phase a proportion of 5 wt. % or less of the active substance is released. Furthermore, the active substance may be released from the pellet with a profile such that, after the lag-phase, the release of the active substance is between 3 and 25 wt. % per hour. The active substance is a metoprolol salt.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: April 14, 2015
    Assignee: ADD Advanced Drug Delivery Technologies Ltd.
    Inventors: Burkhard Schlutermann, Manfred Kohlmeyer
  • Publication number: 20150099002
    Abstract: The present invention relates to means and methods for enhancing intestinal function in poultry, leading to an increase in food conversion ratio and in total weight gain. Particularly, the present invention relates to insulin-containing feed formulations enhancing intestinal function and weight gain in poultry.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 9, 2015
    Inventors: Naim Shehadeh, Lora Eshkar-Sebban, Aviv Hanien, Sharon Devir
  • Patent number: 9000149
    Abstract: The present invention relates to mixtures including hydrophobic microparticles comprising a positively charged polymer (e.g. a polysaccharide such as chitosan) non-covalently bound to an anionic or non-ionic surfactant such as lecithin. The mixtures are useful for reducing cholesterol of an animal, for example a bird such as a chicken or any type of mammal. Methods of manufacture and use of the mixtures are also disclosed herein.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: April 7, 2015
    Assignees: Ben-Bar Technology 2006 Ltd., Miloubar Central Feed Mill Corporation Ltd.
    Inventor: Noach Ben-Shalom
  • Publication number: 20150086623
    Abstract: A controlled-release pharmaceutical composition including first and second groups of microparticles, each of the microparticles including a core including tamsulosin or pharmaceutically acceptable salts thereof, a controlled-release polymer coating layer formed on the core, and an enteric polymer outer layer formed on the controlled-release polymer coating layer, wherein the average thickness of the controlled-release polymer coating layer is different in each of the first and second groups of microparticles, and an oral formulation including the same, are provided. This pharmaceutical composition can easily control the extent of release of an active ingredient depending on changes in pH in the intestinal tract and the release pattern of the active ingredient in the small intestine, thus preventing the active ingredient from being rapidly transferred into the blood to thereby minimize side-effects, and maintaining the effective blood concentration of the active ingredient for a predetermined period of time.
    Type: Application
    Filed: December 1, 2014
    Publication date: March 26, 2015
    Inventors: Ho-Jin Chung, Sang-Yeob Park, Chaul-Min Pai
  • Publication number: 20150086626
    Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed along with a method of preparation therefor. The dosage form comprises active core particles which are individually surrounded by a water insoluble polymer coating which lacks plasticizer.
    Type: Application
    Filed: April 16, 2013
    Publication date: March 26, 2015
    Inventors: Thomas Daniel Reynolds, Boyong Li
  • Publication number: 20150072858
    Abstract: The present disclosure is directed to cellulose ether compositions for film-forming coating applications. A coating composition is provided which contains an aqueous solution of either a very low viscosity cellulose ether or a low-hydroxypropyl cellulose ether, the coating composition having low color. The low viscosity of the cellulose ether component enables the coating composition to contain a high concentration of cellulose ether. Provision of these high concentration cellulose ether coating solutions improves production efficiency by reducing the time required to coat a substrate.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: True L. Rogers, Debora L. Holbrook, Karen A. Coppens, Robert L. Schmitt
  • Patent number: 8975271
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 10, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
  • Patent number: 8975273
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: March 10, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
  • Publication number: 20150064262
    Abstract: Disclosed is a pharmaceutical nitazoxanide composition comprising: (a) an immediate release fraction comprising nitazoxanide non-coated granules or non-granulated powder, and (b) a pH-dependent release fraction comprising granules of nitazoxanide coated with one or more polymers having a pH-dependent solubility.
    Type: Application
    Filed: January 27, 2012
    Publication date: March 5, 2015
    Applicant: SIEGFRIED RHEIN S.A. DE C.V.
    Inventor: Esteban Alejandro Fiore
  • Publication number: 20150064248
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Manish S. Shah, Ray J. DiFalco
  • Publication number: 20150064247
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Manish S. Shah, Ray J. DiFalco
  • Patent number: 8968781
    Abstract: The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features pharmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: March 3, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Walter G. Gowan, Jr., Dennis D. Keith, Sandra O'Connor
  • Patent number: 8962030
    Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: February 24, 2015
    Assignee: Jyant Technologies, Inc.
    Inventors: James W. Lillard, Rajesh Singh, Shailesh Singh
  • Patent number: 8956650
    Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: February 17, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Motohiro Ohta, Eiji Hayakawa, Kunio Ito, Sanji Tokuno, Kiyoshi Morimoto, Yasushi Watanabe
  • Patent number: 8951568
    Abstract: A pharmaceutical granule whose shape is spherical or sphere-like shape with a bulk density of 0.6-1.3 g/ml and a dissolution time of 0.5-5 minutes, which is prepared as follows: mother granules are filled into a fluidized-bed as bed charge; active pharmaceutical ingredients are prepared into a suspension or solution whose viscosity is adjusted to 6.0-9.8 Mpa·S with viscosity adjusting agent; then it is sprayed onto surface of said mother granule to obtain final granule.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: February 10, 2015
    Assignee: Tasly Pharmaceuticals Group Co., Ltd.
    Inventors: Shunnan Zhang, Jianhui Yang, Lina Dong, Hongbo Zhang, Xiaolin Bai, Yan Sun, Ting Li
  • Patent number: 8951554
    Abstract: A microcapsule, a structure including a microcapsule, an article including a microcapsule and a method of preparing microcapsules provided, the microcapsule includes at least one material selected from the group consisting of a magnetic substance, a dielectric substance and a combination thereof. The microcapsule also includes a volatile material.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: February 10, 2015
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Jong-jin Park, Jong-min Kim, Sung-ho Jin
  • Publication number: 20150037423
    Abstract: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 5, 2015
    Inventors: Takashi KURASAWA, Yasuko WATANABE, Yoshihiro OMACHI
  • Patent number: 8945618
    Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Motohiro Ohta, Eiji Hayakawa, Kunio Ito, Sanji Tokuno, Kiyoshi Morimoto, Yasushi Watanabe
  • Patent number: 8927025
    Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: January 6, 2015
    Assignee: Cima Labs Inc.
    Inventor: Ehab Hamed
  • Patent number: 8927017
    Abstract: A method for preparing a gabapentin granulate comprising melt granulating gabapentin with polyethylene glycol having a melting point comprised between 50 and 80° C.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: January 6, 2015
    Assignee: ZAMBON S.p.A.
    Inventors: Luca Rampoldi, Alessandro Grassano
  • Patent number: 8927010
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: January 6, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 8921302
    Abstract: Provided is an aqueous hair cleansing composition, including the following components (A) to (D) and water, in which the aqueous hair cleansing composition has a pH of from 2 to 5 when diluted 20-fold: (A) an anionic surfactant; (B) a cationized hydroxypropyl cellulose having a main chain derived from an anhydroglucose, and having a degree of substitution with cationized ethyleneoxy groups of from 0.01 to 2.9 and a degree of substitution with propyleneoxy groups of from 0.1 to 4.0; (C) an organic solvent selected from (C1) and (C2): (Cl) an aromatic alcohol; and (C2) a polypropylene glycol having a molecular weight of from 200 to 1,000; and (D) a hydroxy monocarboxylic acid or a dicarboxylic acid.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: December 30, 2014
    Assignee: Kao Corporation
    Inventors: Hiroki Mizushima, Azusa Kasuga, Eiji Terada
  • Publication number: 20140377365
    Abstract: Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a formulation of rotigotine that is suitable for administration via oral inhalation. Such methods and compositions are useful in the treatment or amelioration of one or more Parkinson's disease symptom(s).
    Type: Application
    Filed: June 18, 2014
    Publication date: December 25, 2014
    Inventors: Libo WU, Wiwik WATANABE
  • Publication number: 20140377349
    Abstract: The present invention relates to a controlled-release oral dosage form for administration of oxycodone once a day and a method of preparing a controlled-release oral dosage form for administration of oxycodone once a day.
    Type: Application
    Filed: June 29, 2012
    Publication date: December 25, 2014
    Applicant: DEVELCO PHARMA SCHWEIZ AG
    Inventors: Hélène Rey, Marc Fischer, Mathias Scheer, Dirk Kramer